Condition
IrAE
Total Trials
5
Recruiting
3
Active
3
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 5 trials
Late-Stage Pipeline
20%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
4Total
P 2 (3)
P 4 (1)
Trial Status
Recruiting3
Not Yet Recruiting1
Unknown1
Clinical Trials (5)
Showing 5 of 5 trials
NCT06337695Phase 2RecruitingPrimary
Vedolizumab for the Prevention of ICI Related Diarrhea or Colitis in Patients With Cancer
NCT07381634Phase 2Recruiting
The Safety and Efficacy of Ondansetron in Reducing Immune Checkpoint Inhibitor-Related Toxicities
NCT06461780Recruiting
Exploring Physical and Psychological Needs and Quality of Life in Patients With Advanced Cancer Receiving Immunotherapy
NCT07303881Phase 2Not Yet RecruitingPrimary
Golidocitinib for Refractory Immune-related Hematologic Toxicities of Advanced Lung Cancer
NCT06178146Phase 4UnknownPrimary
Thymosin Alpha-1 for irAE Secondary to ICIs
Showing all 5 trials